NCT06626659Completed
Lipoprotein (a) and Vascular Regenerative Cell Content
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
Lp(a)-VRCE is an observational, cross sectional study looking at vessel reparative stem cell content in people with and without elevated lipoprotein (a) \[Lp(a)\]. Specifically, the type and number of these cells in peripheral blood samples will be measured in participants with Lp(a) ≥100 nmol/L and compared to participants with Lp(a) \< 100 nmol/L. Determining the presence or absence of specific cells with blood vessel repair capacity in participants with high Lp(a) will further our knowledge of potential mechanisms through which Lp(a) influences cardiovascular health.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 2 Oct 2024
- Start date
- 5 Oct 2024
- Primary completion date
- 3 Dec 2024
- Lead sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
- Diseases
- Coronary artery disease
- NCT number
- NCT06626659
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 5 Oct 2024 to the primary completion date, 3 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.
- Previously received ribonucleic acid therapy specifically targeting Lp(a).
- On oral steroid therapy (e.g., prednisone or other corticosteroids) or other immunosuppressive agents (e.g., methotrexate).
Other illness
- Any life-threatening disease expected to result in death within two years of consent.
- Uncontrolled hypertension.
- New York Heart Association Class IV heart failure.
- Active liver disease or liver dysfunction.
- Active kidney disease or kidney dysfunction.
- History of hemorrhagic stroke or other major bleeding disorder.
- Active infectious disease requiring systemic antibiotic or anti-viral agents.
- Known acquired immunodeficiency syndrome, such as human immunodeficiency virus.
- Treated autoimmune disorders.
Lab values
- White blood cell count ≥15 x 10\^9/L.
Other
- Unable or unwilling to provide written informed consent or provide a peripheral blood sample.
- Women who are pregnant or nursing.
- Participating in another study/trial that is likely to affect the primary outcome.
Who the study is looking for
- Adults ≥18 years of age and ≤80 years of age who meet either of the following criteria:
- Elevated Lp(a) (defined as greater than or equal to 100 nmol/L)
- Non-elevated Lp(a) (defined as less than 100 nmol/L)
- Willing and able to provide written informed consent and comply with study procedures.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| North York Diagnostic and Cardiac Centre Coordinator of this site? Confirm its status | North York | Canada | Unknown status |
| Diagnostic Assessment Centre Coordinator of this site? Confirm its status | Scarborough Village | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.